Focused ultrasound treatments could increase survival in individuals with glioma
Mené sur 34 patients atteints d'un gliome de haut grade (âge médian : 51,5 ans ; durée médiane de suivi : 44,5 mois ; 47 % d'hommes), cet essai multicentrique de phase I/II évalue la faisabilité et la toxicité d'un traitement combinant des ultrasons focalisés transcrâniens et des microbulles circulantes facilitant le passage d'une chimiothérapie standard par témozolomide
Non-invasive and targeted transcranial focused ultrasound (FUS) treatments combined with systemically administered microbubbles enhance the delivered chemotherapeutic dose within brain tumours, due to reversible blood–brain barrier opening (BBBO).1–3 In preclinical studies, increased drug delivery has led to measurable overall survival benefit in animal models of high-grade glioma.4–7 However, to date, there has been no evidence of prolonged overall survival in individuals with glioma.
In The Lancet Oncology, Graeme F Woodworth and colleagues8 are the first, to our knowledge, to indirectly show both progression-free and overall survival benefit following repeated FUS treatments combined with temozolomide, when compared with an external control cohort receiving standard temozolomide treatment. The team reported the results of a multicentre phase 1/2 trial on the use of microbubble-enhanced FUS (MB-FUS) for enhanced delivery of temozolomide in individuals with high-grade gliomas.
The Lancet Oncology , commentaire en libre accès, 2025